Dan Janney is the managing partner of Alta Partners. Dan Janney joined Alta Partners at its founding in 1996. He has nearly 25 years of successful early stage investing experience in life sciences. Dan’s focus on working with talented entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of 35 companies. Prior to Alta, Dan was a senior investment banker at Montgomery Securities.
Dan is currently on the board of directors of several public and private companies, including Allakos (NASDAQ:ALLK), Be Biopharma, Curasen Therapeutics, ImmuneID, Krystal Biotech (NASDAQ:KYRS), Lassen Therapeutics, Novome Biotechnologies and Prolacta Bioscience. In addition, he led Alta’s investments in Astex Pharmaceuticals (acquired by Supergen), Cellective (acquired by Medimmune), ChemGenex (ASX:CXS acquired by Cephalon), CoTherix (NASDAQ:CTRX acquired by Actellion), Definity Health (acquired by United Health), Dynavax (NASDAQ:DVAX), Endonetics (acquired by Medtronic), Esperion Therapeutics (NASDAQ:ESPR), Ilex Oncology (NASDAQ:ILXO acquired by Millennium Pharmaceuticals), InterMune (NASDAQ:ITMN acquired by Roche), LJL Biosystems (NASDAQ:LJLB acquired by Molecular Devices), Mako Surgical (NASDAQ:MAKO acquired by Stryker) and Triangle Pharmaceuticals (NASDAQ:VIRS acquired by Gilead).
Dan is a member of the president’s council of the J. David Gladstone Institutes and the chair of the board of directors of the California Academy of Sciences. He also serves on the Board of Regents of Georgetown University. He holds a B.A. from Georgetown University and an MBA from the Anderson School at the University of California, Los Angeles.
